🌍 Worldwide🎗️ Cancer & Oncology📡 OpenAlex🕒 Updated November 2, 2026

Most-Cited Cancer Immunotherapy Papers This Year (2026)

As of November 2, 2026, “Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial” leads Most-Cited Cancer Immunotherapy Papers This Year with 93 citations. “Thymic health and immunotherapy outcomes in patients with cancer” is second and “Microbiota-induced T cell plasticity enables immune-mediated tumour control” third.

WhatsApp Telegram X Facebook ⓘ Methodology

🚫 No paid placement📡 Source: OpenAlex🕒 Updated November 2, 2026 ⓘ How we measure

🎗️2

Thymic health and immunotherapy outcomes in patients with cancerSimon Bernatz et al. · Nature · 2026-03-1832 citations

👑

🎗️1

Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trialSreya Duttagupta et al. · Nature Medicine · 2026-01-2893 citations

🎗️3

Microbiota-induced T cell plasticity enables immune-mediated tumour controlTariq Ahmad Najar et al. · Nature · 2026-01-1431 citations

Full ranking

🎗️

Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial ↗ •🏆 Leader

Sreya Duttagupta et al. · Nature Medicine · 2026-01-28

93 citationsCitations

🎗️

Thymic health and immunotherapy outcomes in patients with cancer ↗ •

Simon Bernatz et al. · Nature · 2026-03-18

32 citationsCitations

🎗️

Microbiota-induced T cell plasticity enables immune-mediated tumour control ↗ •

Tariq Ahmad Najar et al. · Nature · 2026-01-14

31 citationsCitations

🎗️

Lactylation stabilizes PD-L1 to promote tumor immune evasion and cell growth ↗ •

Lijun Liang et al. · Cell Death and Disease · 2026-03-21

25 citationsCitations

🎗️

Generalizable AI predicts immunotherapy outcomes across cancers and treatments ↗ •

Wan Xiang Shen et al. · Nature Medicine · 2026-07-03

22 citationsCitations

🎗️

Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study ↗ •

Yifan Zhang et al. · Journal for ImmunoTherapy of Cancer · 2026-03-01

17 citationsCitations

🎗️

Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII) ↗ •

Vanita Noronha et al. · Journal of Clinical Oncology · 2026-01-28

16 citationsCitations

🎗️

AND logic nanoparticle for precision immunotherapy of metastatic cancers ↗ •

Shuyue Ye et al. · Nature Nanotechnology · 2026-03-09

15 citationsCitations

🎗️

BACH2 dosage establishes the hierarchy of stemness and fine-tunes antitumor immunity in CAR T cells ↗ •

Taidou Hu et al. · Nature Immunology · 2026-01-16

14 citationsCitations

🎗️

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy ↗ •

Yangyang Li et al. · Medicine Bulletin · 2026-01-01

14 citationsCitations

How this ranking works

Ranked by citation count (OpenAlex) among research papers published this year whose title or abstract matches this topic. Citations build up over time, so the newest papers rank lower. For information only, not medical advice.

Methodology →

SourceOpenAlex

SignalCitations

Last updatedNov 2, 2026, 12:56 PM UTC

Top 10Citations of papers published this year

Frequently asked questions

What is #1 in Most-Cited Cancer Immunotherapy Papers This Year?

As of November 2, 2026, #1 is “Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial”.

How is this ranking measured?

How often is this chart updated?

Data is re-collected automatically and every page shows its last update date.

Can a brand pay to appear in this ranking?

No. There are no paid placements and no commercial influence on rank.